Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Sculptra: Stimulates your own collagen production to gradually thicken skin and restore volume
AOD-9604 is sold for laboratory, research, or analytical purposes only not for human consumption, veterinary use, or medical applications
Competitive Position Eli Lilly Market Cap: ~$885-930B 2025 Rev Growth: +40-50% Forward P/E: ~31 Positioning: Market leader, oral GLP-1 coming Novo Nordisk Market Cap: ~$204-215B 2025 Rev Growth: +30% Forward P/E: ~12 Positioning: Struggling with competition, stock down 60% from peak Pfizer Market Cap: ~$160B 2025 Rev Growth: Declining Forward P/E: ~12 Positioning: Lost Metsera bid to competition Key Advantages: Tirzepatide (Mounjaro/Zepbound) consistently outperforms Novo's semaglutide (Ozempic/Wegovy) in head-to-head trials First-mover advantage with oral GLP-1 (orforglipron) Manufacturing scale-up: $12.5B+ invested in new facilities (Virginia, Texas, Puerto Rico) Direct-to-consumer platform (LillyDirect) creating pricing flexibility Valuation & Price Targets Current Price: ~$990 Market Cap: ~$885-930B Valuation Framework 2025 Est
All currently marketed anti-diabetic drugs targeting DPP-4 block substrate binding by making hydrogen bonds with the anchoring residues Glu205/Glu206 and occupying the S1 hydrophobic pocket (Figure 7)
Carbonated water, acidulant (citric acid), taurine (0.4%), acidity corrector (sodium citrates), maltodextrin, Panax ginseng root extract (0.08%), flavors, preservatives (potassium sorbate, sodium benzoate), sweeteners (sucralose, acesulfame K), caffeine (0.03) %), vegetable oils (coconut, rapeseed), L-carnitine L-tartrate (0.015%), modified starch, vitamins (niacin, pantothenic acid, B6, B12), sodium chloride, guarana seed extract (0.002%), inositol, dyes (E102, E110)
Detalles del producto Referencias especficas ean13 0033984005709 Reseas de clientes (0) Enviar resea Todava no hay reseas disponibles
